The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized phase II study of gemcitabine monotherapy versus gemcitabine with an EPA-enriched oral supplement in advanced pancreatic cancer.
Makoto Ueno
No relevant relationships to disclose
Satoshi Kobayashi
No relevant relationships to disclose
Shinichi Ohkawa
No relevant relationships to disclose
Ryo Kameda
No relevant relationships to disclose
Tomoko Andou
No relevant relationships to disclose
Kazuya Sugimori
No relevant relationships to disclose
Haruo Miwa
No relevant relationships to disclose
Ryonho Ko
No relevant relationships to disclose
Katsuaki Tanaka
No relevant relationships to disclose
Masataka Taguri
No relevant relationships to disclose
Satoshi Morita
No relevant relationships to disclose